Skip to Content

Alecensa (alectinib) Disease Interactions

There are 5 disease interactions with Alecensa (alectinib):

Moderate

Alectinib (Includes Alecensa) ↔ Bradycardia

Moderate Potential Hazard, Moderate plausibility

Applies to: Heart Block, Arrhythmias

Cases of bradycardia have been reported in patients treated with alectinib. It is recommended to monitor heart rate and blood pressure regularly. Dose modification is not required in cases of asymptomatic bradycardia. In cases of symptomatic bradycardia that is not life-threatening, withhold therapy until recovery to asymptomatic bradycardia or to a heart rate of 60 bpm or above and evaluate concomitant medications known to cause bradycardia, as well as anti-hypertensive medications. If attributable to a concomitant medication, resume alectinib at a reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of 60 bpm or above, with frequent monitoring as clinically indicated. Permanently discontinue alectinib in case of recurrence. Permanently discontinue alectinib in cases of life-threatening bradycardia if no contributing concomitant medication is identified.

Moderate

Alectinib (Includes Alecensa) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

No dose adjustment is recommended for patients with mild hepatic impairment. It is recommended to monitor liver function tests including ALT, AST, and total bilirubin every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations. It might be necessary to withhold therapy and resume at a reduced dose, or permanently discontinue treatment based on the severity of the adverse events. Care should be exercised when using alectinib in patients with moderate or severe hepatic impairment as its safety has not been studied in these patients.

Moderate

Alectinib (Includes Alecensa) ↔ Myalgia

Moderate Potential Hazard, Moderate plausibility

Applies to: Myopathy

Elevations of Creatine Phosphokinase (CPK) have been reported with the use of alectinib. It is recommended to watch closely for signs and symptoms of CPK elevation and to advise patients to report any unexplained muscle pain, tenderness, or weakness. Assess CPK levels regularly as clinically indicated in patients reporting symptoms. Based on the severity of the CPK elevation, withhold therapy and then resume or reduce dose.

Moderate

Alectinib (Includes Alecensa) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

No dose adjustment is recommended for patients with mild or moderate renal impairment. Care should be exercised when using alectinib in patients with severe renal impairment or end-stage renal disease as its safety has not been studied in these patients.

Moderate

Multikinase Inhibitors (Includes Alecensa) ↔ Lung Toxicity

Moderate Potential Hazard, Moderate plausibility

Applies to: Interstitial Pneumonitis, Pulmonary Impairment

The use of certain multikinase inhibitors has been associated with pulmonary toxicity. Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported. Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation. If ILD is confirmed, permanently discontinue these agents and institute appropriate measures. Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.

Alecensa (alectinib) drug Interactions

There are 96 drug interactions with Alecensa (alectinib)

Alecensa (alectinib) alcohol/food Interactions

There is 1 alcohol/food interaction with Alecensa (alectinib)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide